Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
US FDA Accepts NDA for Belite’s Oral Stargardt Candidate, Grants Priority Review
Belite Bio announced Aug. 11 that the US FDA had accepted its new drug application (NDA) for its oral Stargardt treatment candidate, tinlarebant. The agency granted priority review, and set a Presc...
Q2-2026 Ophthalmic Revenue Roundup for Alcon, Tarsus, Immunocore, Harrow, Sight Sciences, and ANI
Alcon reported Aug. 10 that its Q2-2026 net sales totaled $2.8 billion, an 8 percent increase over $2.6 billion in Q2-2025. Alcon also announced that it had discontinued work on the PowerVision Flu...
Oculis Buys Out Global Rights to Privosegtor from Accure
Swiss company Oculis announced Aug. 10 that it would obtain worldwide development and commercialization rights to privosegtor as part of an asset purchase agreement with Spain’s Accure Therapeutics...
Italy’s Alfasigma to Acquire Nordic Pharma, Maker of Lacrifill Canalicular Gel
Italian pharmaceutical company Alfasigma announced Aug. 11 that it would acquire 100 percent of the shares of Nordic Group BV (Nordic Pharma) and its subsidiaries from Sever Life Sciences. Financia...
Nicox Partner Ocumension Submits NDA in China for Glaucoma Drop
France’s Nicox announced Aug. 10 that its partner Ocumension Therapeutics, of China, had submitted a new drug application (NDA) to China’s National Medical Products Administration for NCX 470, a ni...
US FDA Gives Green Light to Trial of Ractigen’s saRNA Candidate in PVR
China’s Ractigen Therapeutics reported on July 31 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I clinical trial of ...
US FDA Grants RMAT Status to Ocugen’s Gene Therapy Candidate for GA
Ocugen announced July 29 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to OCU410, the company’s subretinal gene therapy candidate for geographic atrophy (GA)...
2026-2027 Ophthalmic Meetings Calendar
Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.
Tarsus to Acquire Alkeus Pharmaceuticals in Deal Worth up to $800 Million
Tarsus Pharmaceuticals, maker of Xdemvy, announced Aug. 6 that it would acquire Alkeus Pharmaceuticals in a cash-and-stock deal worth up to $800 million. Under the deal, Tarsus will pay $450 milli...
Q2-2026 Ophthalmic Revenue Roundup for Regeneron, Amgen, Hoya, Astellas, Novartis, Lumibird, Ocular Therapeutix, and Xbrane
Regeneron, of Tarrytown, New York, reported July 30 that its Q2-2026 US revenue for Eylea HD and Eylea 2 mg was $1.0 billion, a 12 percent decrease from $1.15 billion in Q2-2025. Eylea HD accounted...
Biocon Launches Eylea Biosimilar Yesafili in the US
India’s Biocon Limited announced on Aug. 3 the commercial launch of Yesafili (aflibercept-jbvf), a biosimilar to Eylea 2 mg, in the US. Yesafili was among a flurry of Eylea biosimilars approved by ...
Harrow Acquires Global Rights to Tyrvaya Nasal Spray for Dry Eye
Harrow, of Nashville, Tennessee, announced Aug. 6 that it would acquire global rights to Tyrvaya (varenicline) nasal spray for dry eye from Viatris. Under the deal, Harrow will pay $30 million up f...
Past News Stories
Sight Sciences Gains US FDA 510(k) Clearance for Omni Ultra Glaucoma Device
Sight Sciences announced Aug. 4 that it had gained 510(k) clearance from the US FDA for the Omni Ultra surgical system. Sight Sciences, of Menlo Park, California, said the Ultra is indicated for ca...
Topcon Gains CE Marking for Gaia Ultra-widefield Retinal Imager
Topcon Healthcare announced July 17 that it had gained CE marking in Europe for its Gaia ultra-widefield retinal imaging device. Topcon says Gaia offers true-color fundus imaging, with a 209-degree...
Aravind, Alcon Open Centre of Excellence for Vitreoretinal Surgery Training in India
Aravind Eye Care System and Alcon reported July 24 that they had launched the Aravind Alcon Global Centre of Excellence for Vitreoretinal Surgery Training in Coimbatore, India. The move marks the s...
STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer
STAAR Surgical, of Lake Forest, California, reported Aug. 4 that it had appointed Warren Foust as president and chief executive officer. Foust and Deborah Andrews, STAAR’s chief financial officer, ...
Roche Receives Positive CHMP Opinion for Susvimo Sustained-Release Wet AMD Treatment
Swiss drugmaker Roche announced July 24 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended marketing authorization in the European Union for ...
Nicox Partner Kowa Submits NDA to US FDA for Glaucoma Drop
France’s Nicox announced July 1 that its partner Kowa, of Japan, had submitted a new drug application to the US FDA for NCX 470, also known as K-911, a nitric oxide-donating bimatoprost eye drop ca...
US FDA Approves Outlook’s Lytenava (Bevacizumab) for Wet AMD
Outlook Therapeutics announced July 24 that it had gained US FDA approval for Lytenava (bevacizumab-vikg) to treat wet age-related macular degeneration (AMD). The news comes after years of regulato...
Glaukos Changes US Regulatory Pathway for PreserFlo, Completes Enrollment in 510(k) Study
Glaukos reported July 27 that it had completed patient enrollment in a 510(k) pivotal study for the PreserFlo MicroShunt. The glaucoma drainage device is implanted ab externally to increase outflow...
Q2-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Roche, and Glaukos
Bausch + Lomb reported July 29 that its Q2-2026 revenue was $1.4 billion, a 9 percent increase over $1.3 billion in Q2-2025, driven by a 64 percent increase in implantables, including a 175 percent...
Science Corp. Launches Prima Retinal Implant in Europe
Science Corporation reported July 22 that it had launched its Prima retinal implant in Europe for patients with geographic atrophy (GA) caused by age-related macular degeneration (AMD). The company...
Bausch + Lomb Launches EyeGility Preloaded IOL Inserter in the US
Bausch + Lomb announced July 16 that it had launched the EyeGility Inserter preloaded IOL (intraocular lens) delivery system in the US. The inserter is available now with the enVista Aspire interme...
Marketing Application Submitted in Australia for Orasis’ Presbyopia Drop
Orasis Pharmaceuticals announced July 15 that its partner Aspen Australia had submitted a new drug application to Australia’s Therapeutic Goods Administration for Orasis’ pilocarpine hydrochloride ...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.